RecruitingHepatocellular Carcinoma (HCC)
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Eligible age
18+ yrs
Accepts
All genders
Locations
7 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Sponsor: Bristol-Myers Squibb
You may qualify if…
- ✓ Participants must have a histologically confirmed diagnosis of locally advanced or unresectable Hepatocellular Carcinoma (HCC).
- ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- ✓ Participants must have no prior systemic therapy for advanced/ unresectable HCC.
- ✓ Participants must have measurable disease as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.
You may not qualify if…
- ✕ Participants must not have significant bleeding or coagulation disorders or other obvious bleeding risk evidence.
- ✕ Participants must not have an organ transplant or autoimmune disease.
- ✕ Other protocol-defined Inclusion/Exclusion criteria apply.
Where it's recruiting
California
Los Angeles
Illinois
Chicago
New Jersey
Hackensack
New York
Mineola
Oregon
Portland
Tennessee
Nashville
Washington
Seattle
Source: ClinicalTrials.gov · NCT07291076 · last updated 2026-06-02